Welcome to our dedicated page for Lifemd news (Ticker: LFMDP), a resource for investors and traders seeking the latest updates and insights on Lifemd stock.
LifeMD, Inc. (LFMDP) provides a centralized news hub for investors and healthcare professionals tracking advancements in integrated telehealth solutions. This resource aggregates official announcements regarding service expansions, technology innovations, and operational milestones within LifeMD's HIPAA-compliant ecosystem.
Access timely updates on virtual care initiatives, including developments in remote diagnostics, digital prescription systems, and secure provider-patient communication platforms. The curated news collection enables stakeholders to monitor strategic partnerships, regulatory compliance achievements, and enhancements to the company's clinician-centric EMR infrastructure.
All content reflects LifeMD's commitment to advancing accessible healthcare through AES-encrypted telemedicine services and custom diagnostic equipment. Bookmark this page for verified updates about operational developments that shape the company's position in the digital health sector.
LifeMD (Nasdaq: LFMD) will join the Russell 3000 Index after the 2024 Russell U.S. Indexes annual reconstitution. This inclusion will take effect at the start of U.S. equity markets on July 1, 2024. The Russell 3000 Index captures the 4,000 largest U.S. stocks by market capitalization. Membership means automatic inclusion in either the Russell 1000 or Russell 2000 Index, along with the corresponding growth and value style indexes. This inclusion reflects LifeMD's growth in providing affordable primary care and other healthcare services. The Russell indexes, managed by FTSE Russell, serve as benchmarks for approximately $10.5 trillion in assets. The annual rebalancing ensures the indexes accurately represent market segments.
LifeMD reported a strong first quarter of 2024 with a 33% revenue increase year-over-year to $44.1 million. Telehealth revenue grew by 53% compared to the previous year. The company raised full-year revenue guidance to at least $205 million, showing growth in all business segments. Weight management subscribers surpassed 50,000, with cash-adjusted EBITDA at $4.8 million, a 108% increase. The company generated $5.2 million in cash flow and had a $2.0 million net increase in cash during the quarter.
LifeMD, Inc.® (Nasdaq: LFMD) partners with Withings Health Solutions to enhance virtual patient care for GLP-1 weight-loss patients. By providing advanced in-home health monitoring devices, LifeMD aims to improve patient outcomes through real-time data, drive compliance, and enhance clinical decision-making. This partnership sets a new standard in virtual care, revolutionizing weight management patient care and supporting chronic care management.
LifeMD, Inc. announced the appointment of Dr. Calum MacRae, a renowned clinician and researcher at Harvard Medical School, to its Board of Directors. Dr. MacRae's expertise in cardiology and chronic disease management will enhance the company's virtual primary care services. His track record in implementing innovative solutions and leveraging technology in healthcare is expected to drive LifeMD's growth and improve patient care.
FAQ
What is the current stock price of Lifemd (LFMDP)?
